A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
NCT ID: NCT00034268
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2002-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone.
2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs.
3. Whether LY900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone.
It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed.
LY900003 may not add any benefit to gemcitabine plus cisplatin.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY900003
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to visit the doctor's office
3. At least 18 years of age
4. Adequate kidney, adrenal, and liver function
Exclusion Criteria
2. Central nervous system tumors
3. Pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hot Springs, Arkansas, United States
Springdale, Arkansas, United States
Los Angeles, California, United States
Santa Rosa, California, United States
Denver, Colorado, United States
Fort Collins, Colorado, United States
Wilmington, Delaware, United States
Tucker, Georgia, United States
Indianapolis, Indiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Robbinsdale, Minnesota, United States
Latham, New York, United States
New York, New York, United States
Arlington, Texas, United States
Dallas, Texas, United States
Abingdon, Virginia, United States
Marshfield, Wisconsin, United States
Mendoza, Mendoza Province, Argentina
Ciudad de Buenos Aires, , Argentina
Brasschaat, , Belgium
Edegem, , Belgium
Liège, , Belgium
Merksem, , Belgium
Ostend, , Belgium
Las Condes, Santiago Metropolitan, Chile
Brest, , France
Nice, , France
Paris, , France
Pessac, , France
Rouen, , France
Saint-Herblain, , France
Tours, , France
Vandœuvre-lès-Nancy, , France
Frankfurt am Main, Hesse, Germany
Augsburg, , Germany
Berlin, , Germany
Freiburg im Breisgau, , Germany
Grobhansdorf, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Hofheim, , Germany
Koin, , Germany
Leipzig, , Germany
München, , Germany
Neustadt/Suedharz, , Germany
Trier, , Germany
Ulm, , Germany
Budapest, , Hungary
Bangalore, Karnataka, India
Mumbai, Maharashtra, India
Pune, Maharashtra, India
Ludhiana, Punjab, India
New Dehli, , India
Rozzano, Milano, Italy
Perugia, , Italy
Pisa, , Italy
Ravenna, , Italy
Roma, , Italy
's-Hertogenbosch, , Netherlands
Amsterdam, , Netherlands
Arnhem, , Netherlands
Groningen, , Netherlands
Nieuwegien, , Netherlands
Zwolle, , Netherlands
Oslo, , Norway
Otwock, Masovian Voivodeship, Poland
Warsaw, Warszawa, Poland
Krakow-Nowa Huta, , Poland
Wroclaw, , Poland
Bayamón, , Puerto Rico
Ponce, , Puerto Rico
Cluj-Napoca, Cluj, Romania
Moscow, , Russia
Overport, Durban, South Africa
Arcadia, Gauteng, South Africa
Durban, , South Africa
Parklands, , South Africa
Tygerberg, , South Africa
Alicante, Alicante, Spain
Badalona, Barcelona, Spain
Barcelona, Barcelona, Spain
Sabadell, Barcelona, Spain
Madrid, Madrid, Spain
Palma de Mallorca, Palma de Mallorca, Spain
Oviedo, Principality of Asturias, Spain
Valencia, Valenica, Spain
Barakaldo, Vizcaya, Spain
Zaragoza, Zaragoza, Spain
Linköping, , Sweden
Lund, , Sweden
Stockhlom, , Sweden
Zurich, , Switzerland
Taoyuan District, Kuei-Shan, Taiwan
Taichung, Taiwan, Province of China, Taiwan
Taipei, , Taiwan
Hull, East Yorkshire, United Kingdom
London, Greater London, United Kingdom
Southampton, Hampshire, United Kingdom
Nottingham, Nottinghamshire, United Kingdom
Glasgow, Scotland, United Kingdom
Cardiff, South Glamorgan, United Kingdom
Newcastle upon Tyne, Tyneside, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H7X-MC-JVAA
Identifier Type: -
Identifier Source: secondary_id
6428
Identifier Type: -
Identifier Source: org_study_id